On the role of CNTF as a potential therapy for retinal degeneration: Dr. Jekyll or Mr. Hyde?

Adv Exp Med Biol. 2008:613:45-51. doi: 10.1007/978-0-387-74904-4_4.

Author

William A Beltran¹

Affiliation

¹ Section of Ophthalmology, Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. wbeltran@vet.upenn.edu

PMID: 18188927
DOI: 10.1007/978-0-387-74904-4_4

No abstract available

Publication types

Research Support, N.I.H., Extramural
Review

MeSH terms

Animals
Cell Survival / drug effects
Ciliary Neurotrophic Factor / therapeutic use*
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Disease Models, Animal
Dog Diseases / therapy*
Dogs
Electroretinography
Humans
Macular Degeneration / pathology
Macular Degeneration / therapy
Neuroprotective Agents / therapeutic use*
Night Blindness / genetics
Night Blindness / therapy
Night Blindness / veterinary*
Photoreceptor Cells / drug effects
Retina / drug effects
Retinal Degeneration / drug therapy*
Retinal Degeneration / genetics

Substances

Ciliary Neurotrophic Factor
Neuroprotective Agents